Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.

Science advances - 1 Feb 2020

Aldonza Mark Borris D, Ku Jayoung, Hong Ji-Young, Kim Donghwa, Yu Seung Jung, Lee Min-Seok, Prayogo Monica Celine, Tan Stephanie, Kim Dayeon, Han Jinju, Lee Sang Kook, Im Sung Gap, Ryu Han Suk, Kim Yoosik

Abstract excerpt

Secondary drug resistance stems from dynamic clonal evolution during the development of a prior primary resistance. This collateral type of resistance is often a characteristic of cancer recurrence. Yet, mechanisms that drive this collateral resistance and their drug-specific trajectories are still poorly understood. Using resistance selection and small-scale pharmacological screens, we find that cancer cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycolysis

Share to Induction Chemotherapy

Share to Molecular Targeted Therapy

Share to Neoplastic Stem Cells

Share to Paclitaxel

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 32083171
DOI: 10.1126/sciadv.aav7416
PMCID: PMC7007258

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.PMID 32083171Read ↗

Cellular adaptation to cancer therapy along a resistance continuum.Semantic proximity Read ↗

Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.Semantic proximity Read ↗

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.Semantic proximity Read ↗

Metronomic and single high-dose paclitaxel treatments produce distinct heterogenous chemoresistant cancer cell populationsSemantic proximity Read ↗

Multilevel Mechanisms of Cancer Drug Resistance.Semantic proximity Read ↗

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.Semantic proximity Read ↗

Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Semantic proximity Read ↗

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.Semantic proximity Read ↗

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.